These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 8624269)

  • 21. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markers of bone resorption in patients treated with pamidronate.
    Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
    Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response?
    Martinetti A; Ripamonti C; Miceli R; Seregni E; Mariani L; De Conno F; Bajetta E; Bombardieri E
    Oncol Rep; 2007 Jun; 17(6):1533-40. PubMed ID: 17487415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model.
    Wada N; Ishii S; Ikeda T; Kitajima M
    Breast Cancer; 2004; 11(3):282-7. PubMed ID: 15550847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.
    Morabito N; Gaudio A; Lasco A; Vergara C; Tallarida F; Crisafulli G; Trifiletti A; Cincotta M; Pizzoleo MA; Frisina N
    Osteoporos Int; 2003 Jul; 14(6):500-6. PubMed ID: 12750879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study.
    Klein GL; Wimalawansa SJ; Kulkarni G; Sherrard DJ; Sanford AP; Herndon DN
    Osteoporos Int; 2005 Jun; 16(6):631-5. PubMed ID: 15452689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
    Coleman RE; Houston S; Purohit OP; Rubens RD; Kandra A; Ford J
    Eur J Cancer; 1998 May; 34(6):820-4. PubMed ID: 9797692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclical pamidronate infusions in postmenopausal osteoporosis.
    Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
    Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of disodium pamidronate in the management of bone pain due to malignancy.
    Groff L; Zecca E; De Conno F; Brunelli C; Boffi R; Panzeri C; Cazzaniga M; Ripamonti C
    Palliat Med; 2001 Jul; 15(4):297-307. PubMed ID: 12054147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
    Lipton A; Glover D; Harvey H; Grabelsky S; Zelenakas K; Macerata R; Seaman J
    Ann Oncol; 1994; 5 Suppl 7():S31-5. PubMed ID: 7532991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
    Engler H; Koeberle D; Thuerlimann B; Senn HJ; Riesen WF
    Clin Chem Lab Med; 1998 Nov; 36(11):879-85. PubMed ID: 9877095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
    Clarke NW; McClure J; George NJ
    Br J Urol; 1992 Jan; 69(1):64-70. PubMed ID: 1737255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates for metastatic bone pain.
    Body JJ
    Support Care Cancer; 1999 Jan; 7(1):1-3. PubMed ID: 9926966
    [No Abstract]   [Full Text] [Related]  

  • 39. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
    Thürlimann B; Morant R; Jungi WF; Radziwill A
    Support Care Cancer; 1994 Jan; 2(1):61-5. PubMed ID: 8156259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
    Conte PF; Latreille J; Mauriac L; Calabresi F; Santos R; Campos D; Bonneterre J; Francini G; Ford JM
    J Clin Oncol; 1996 Sep; 14(9):2552-9. PubMed ID: 8823335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.